


CLAIMS

1. A compound according to Formula I, wherein



Formula I

- 5 X is O, NOH, NO(1-4C)alkyl, NO(1-4C)acyl;
 A1-A5 are C, substituted with R1, or N, provided that at least one and not
 more than three of A1-A5 are N; or
 one or two of A1, A2 and A5 are N, and the others are C, substituted with
 R1, and A3 and A4 together represent a fused benzo ring or a fused five- or
 10 six-membered nitrogen-containing aromatic ring, both optionally substituted
 with one or more halogen and/or (1-4C)alkyl;
 each R1 is independently selected from H, halogen, (1-4C)alkyl and
 (1-4C)alkoxy;
 R2 is H, (1-4C)alkyl, or (1-6C) alkenyl, both optionally substituted with an
 15 (6-10C)aryl group, which is optionally substituted with one or more halogen
 and/or (1-4C)alkyl; and
 R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and
 R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or
 more halogen and/or (1-4C)alkyl; or
 20 R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and
 R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or
 more halogen and/or (1-4C)alkyl); or
 R2 is H or (1-4C)alkyl; and

38

R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring;

R5 is H or (1-4C)alkyl;

or a pharmaceutically acceptable salt and/or hydrate form and/or prodrug thereof.

5

2. A compound according to claim 1 characterised in that A1-A5 are C, substituted with R1, or N, provided that at least one and not more than three of A1-A5 are N.

10

3. A compound according to claim 1 characterised in that one or two of A1, A2 and A5 are N, and the others are C, substituted with R1, and A3 and A4 together represent a fused benzo ring or a fused five- or six-membered nitrogen-containing aromatic ring, both optionally substituted with halogen and/or (1-4C)alkyl.

15

4. A compound according to claim 1 characterised in that R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an (6-10C)aryl group, which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.

20

5. A compound according to claim 1, characterised in that R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.

25

6. A compound according to claim 1, characterised in that R2 is H or (1-4C)alkyl; and

30

39

R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.

- 5 7. A compound according to claim 2, characterised in that
R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an
(6-10C)aryl group, which is optionally substituted with one or more halogen
and/or (1-4C)alkyl; and
R3 is H or (1-4C)alkyl optionally substituted with one or more halogen; and
10 R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or
more halogen and/or (1-4C)alkyl.
- 15 8. A compound according to claim 2, characterised in that
R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and
R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or
more halogen and/or (1-4C)alkyl.
- 20 9. A compound according to claim 2, characterised in that
R2 is H or (1-4C)alkyl; and
R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated
carbocyclic ring.
- 25 10. A compound according to claim 3, characterised in that
R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an
(6-10C)aryl group which is optionally substituted with one or more halogen
and/or (1-4C)alkyl; and
R3 is H or (1-4C)alkyl optionally substituted with one or more halogen; and
R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or
more halogen and/or (1-4C)alkyl.
- 30 11. A compound according to claim 3, characterised in that
R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and

40

R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.

5

12. A compound according to claim 3, characterised in that
R2 is H or (1-4C)alkyl; and
R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.

10

13. A compound according to claim 1, characterised in that X is O.

14. A compound according to claim 4, characterised in that R4 is cyclopropyl.

15. A compound according to claim 5, characterised in that R4 is cyclopropyl.

15

16. A compound according to claim 2, characterised in that A1, A3, A4 and A5 are C, substituted with R1, and A2 is N.

17. A compound according to claim 4, characterised in that

20

18. A compound according to claim 13, characterised in that
A1, A3, A4 and A5 are C, substituted with R1, and A2 is N;
R2 is H, (1-4C)alkyl or (1-4C)alkenyl; and
R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and
R4 is cyclopropyl; or
R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and
R4 is cyclopropyl.

25

30

19. A compound according to claim 13, characterised in that
A1, A3, A4 and A5 are C;
A2 is N;
R1 is H

41

R2 is methyl;
R3 is H;
R4 is cyclopropyl;
R5 is H.

5

20. A compound according to claim 13, characterised in that

A1, A3, A4 and A5 are C;

A2 is N;

R1 is H

10

R2 is ethenyl;

R3 is H;

R4 is cyclopropyl;

R5 is H .

15

21. The compound of any one of claims 1-20 for use in therapy.

22. A pharmaceutical composition comprising a compound according to any one of claims 1-20 and a pharmaceutically acceptable carrier.

20

23. A pharmaceutical composition according to claim 22 for contraception.

24. A pharmaceutical composition according to claim 22 for hormone replacement therapy.

25

25. A pharmaceutical composition according to claim 22 for the treatment of a gynaecological disorder.

26. A use of a compound according to any one of claims 1-20 for the manufacture of a medicament.

30

27. A use of a compound according to any one of claims 1-20 for the manufacture of a contraceptive.

42

28. A use according to claim 26 wherein the medicament is for hormone replacement therapy or for the treatment of a gynaecological disorder.
- 5 29. A method of contraception comprising administering a pharmaceutically effective amount of a compound according to any one of claims 1-20 to a subject in need thereof.
- 10 30. A method of treating a gynaecological disorder comprising administering a pharmaceutically effective amount of a compound according to any one of claims 1-20 to a subject in need thereof.